INTRODUCTION: Core disease activity indicators of @entity309 ( @entity309 ) have been found to be limited in predicting joint destruction progression. @entity1549 plays an essential role in joint destruction and was found elevated in some remission @entity1 . We aimed to monitor dynamic core disease activity indicators and serum @entity1549 for one year and evaluate their value for predicting radiographic progression. METHODS: @entity1 with active @entity309 (Simplified disease activity index   >   3.3) were treated according to the treat-to-target strategy. Serum @entity1549 was detected by enzyme-linked immunosorbent assay and clinical data were collected simultaneously at 0, 1st, 3rd, 6th and 12th month. X-ray assessment of hand/wrist was repeated at baseline and the 12th month and a change of total Sharp score   >   0.5 units was defined as radiographic progression. RESULTS: Fifty-six @entity1 completed one year follow-up and 29  % showed radiographic progression. Although not significantly different at baseline, serum @entity1549 and all core disease activity indicators, except for erythrocyte sedimentation rate, at the 12th month were significantly higher in the progressive group than in the non-progressive group. Among sixteen progressive @entity1 , 69  % achieved the therapeutic target and 56  % had continuous elevated serum @entity1549 , 38  % had continuous elevated serum @entity1549 and normal @entity1851 ( @entity1851 ) at the 6th month. Log-rank tests and repeated measures analysis revealed a significant difference in dynamic serum @entity1549 between progressive and non-progressive @entity1 . Receiver operating characteristic curve and univariate logistic regression analysis showed that elevated serum @entity1549 at 0, 1st, 3rd and 6th months, compared with @entity1851 at the 1st month, were significant predictors for one-year radiographic progression ( @entity1549 odds ratio (OR):10.500   ~   27.000, all P   <   0.05; @entity1851 : OR   =   7.400, P   =   0.011). CONCLUSIONS: Our data showed that continuously elevated serum @entity1549 for 3   ~   6  months predicted one-year radiographic progression which implied that monitoring of dynamic serum @entity1549 combined with core disease activity indicators may be more helpful for predicting radiographic progression and treatment decision in @entity309 .

Continuously elevated serum matrix metalloproteinase-3 for 3   ~   6  months predict one-year radiographic progression in XXXX : a prospective cohort study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity1549 :: ('4314', 'Gene') :: ['Matrix metalloproteinase (MMP) 3', 'MMP-3'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
